As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At BioRestorative Therapies, a filing with the SEC revealed that on Thursday, Dale Broadrick purchased 120,000 shares of BRTX, for a cost of $1.35 each, for a total investment of $162,255. BioRestorative Therapies is trading up about 3.9% on the day Friday. Before this latest buy, Broadrick bought BRTX on 4 other occasions during the past twelve months, for a total cost of $57,670 at an average of $1.94 per share.
And at Lineage Cell Therapeutics, there was insider buying on Thursday, by Director Don M. Bailey who bought 96,155 shares at a cost of $1.04 each, for a trade totaling $100,001. This purchase marks the first one filed by Bailey in the past year. Lineage Cell Therapeutics is trading up about 2.3% on the day Friday. Bailey was up about 9.6% on the buy at the high point of today's trading session, with LCTX trading as high as $1.14 in trading on Friday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
